Aramesh Kiarash
Dev World Bioeth. 2015 Aug;15(2):107-12. doi: 10.1111/dewb.12053. Epub 2014 Apr 11.
During the past two decades, Iran has experienced a noteworthy growth in its biomedical research sector. At the same time, ethical concerns and debates resulting from this burgeoning enterprise has led to increasing attention paid to biomedical ethics. In Iran, Biomedical research ethics and research oversight passed through major periods during the past decades, separated by a paradigm shift. Period 1, starting from the early 1970s, is characterized by research paternalism and complete reliance on researchers as virtuous and caring physicians. This approach was in concordance with the paternalistic clinical practice of physicians outside of research settings during the same period. Period 2, starting from the late 1990s, was partly due to revealing of ethical flaws that occurred in biomedical research in Iran. The regulatory and funding bodies concluded that it was not sufficient to rely solely on the personal and professional virtues of researchers to safeguard human subjects' rights and welfare. The necessity for independent oversight, emphasized by international declarations, became obvious and undeniable. This paradigm shift led to the establishment of research ethics committees throughout the country, the establishment of academic research centers focusing on medical ethics (MEHR) and the compilation of the first set of national ethical guidelines on biomedical research-one of the first and most important projects conducted by and in the MEHR. Although not yet arrived, 'period 3' is on its way. It is predictable from the obvious trends toward performance of high-quality clinical research and the appearance of a highly educated new generation, especially among women.
在过去二十年中,伊朗的生物医学研究领域取得了显著发展。与此同时,这一蓬勃发展的事业引发的伦理问题和争论,使得生物医学伦理受到了越来越多的关注。在伊朗,生物医学研究伦理与研究监督在过去几十年经历了主要阶段,各阶段之间存在范式转变。第一阶段始于20世纪70年代初,其特点是研究家长主义以及完全依赖研究人员,将其视为品德高尚且关怀备至的医生。这种方法与同一时期研究环境之外医生的家长式临床实践相一致。第二阶段始于20世纪90年代末,部分原因是伊朗生物医学研究中出现的伦理缺陷被揭露。监管和资助机构得出结论,仅依靠研究人员的个人和职业品德来保护人类受试者的权利和福利是不够的。国际宣言所强调的独立监督的必要性变得明显且不可否认。这种范式转变导致在全国范围内设立了研究伦理委员会,建立了专注于医学伦理的学术研究中心(MEHR),并编纂了第一套生物医学研究国家伦理准则——这是MEHR开展并参与的首批也是最重要的项目之一。尽管“第三阶段”尚未到来,但已在路上。从高质量临床研究的明显趋势以及新一代,尤其是女性中高学历群体的出现可以预测到这一点。